"The Hill" gets it (partially) wrong on FDA & Preemption

"The Hill" today ran an article on June 15, titled "Trial lawyers’ win on suit provision threatens FDA bill." The article discusses a provision added to several discussion drafts of an unidentified FDA bill (presumably Prescription Drug User Fee Act [PDU

Judge approves amended First Databank settlement in case brought by PAL members

n June 2005 and February 2006, members of the PAL coalition AFSCME District Council 37 Health & Security Plan and New England Carpenters Health Benefits Fund filed lawsuits alleging that First Databank and McKesson carried out an illegal scheme from 2002

Community Catalyst & Robert Wood Johnson Foundation Announce $12M Effort to Support Consumer Advocacy for Health Care Coverage

Prescription Access Litigation's parent organization, Community Catalyst, today announced "Consumer Voices for Coverage," a major new initiative to support state health care advocacy in certain states. The program was launched today with a Call for Propo

State AG settlement on Ovcon reverse payment case shows need for further reform

The Attorneys General of 34 states and DC announced on Tuesday a $5.5 million settlement with Warner Chilcott. The settlement addresses the AGs' claims that Warner paid Barr laboratories $20 Million to not bring a generic version of the contraceptive Ovco

Bitter Pill Award winner Lunesta has most recalled drug ad

One of last year's Bitter Pill Awards honorees, Lunesta, has the dubious distinction of having the most recalled and most remembered drug ads on TV, according to IAG Research. In 2006, we gave Lunesta and Ambien our "While You Were Sleeping Award: For Ov

NPR's Marketplace features PAL Director discussing GSK's alli

NPR's Marketplace morning featured two stories today on the launch of GSK's over-the-counter weight loss drug alli. One of these stories featured Prescription Access Litigation director Alex Sugerman-Brozan discussing alli and why it should not be availab

NY Daily News dishes on Alli, highlights PAL's "With Allies Like this, Who Needs Enemas?" Award

Today's New York Daily News features a great article on the promise and pitfalls of GlaxoSmithKline's over-the-counter weight loss drug, Alli, ("Don't Swallow the Hype," by Julian Kesner) which is due to launch on Friday. Of course, we like the article

Alli's side effects -- er, "treatment effects"

GlaxoSmithKline has been nothing but forthright when it comes to the side effects of its new Over-the-Counter weight loss drug, alli (which earned the “With Allies Like This, Who Needs Enemas?” Award from PAL earlier this week) - they've admitted that it

Judge certifies class action in Norvir case

In October 2004, PAL member SEIU Health & Welfare Fund filed a class action lawsuit against Abbott Laboratories, alleging that Abbott's 400% price increase for its HIV/AIDS drug Norvir violated federal antitrust laws. (In re Abbott Laboratories Norvir Ant